Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Herman

Infectious Disease Hillsborough, NJ Medical Doctor

NPI 1326014390 CMS profile 59398

105 Raider Blvd, Suite 101, Hillsborough, NJ 08844

Open in the dashboard

General payments

$4,186

173 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Herman of Hillsborough, NJ is reported in the CMS Open Payments database as having received $4,186 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $783 23
2024 General $857 27
2023 General $700 22
2022 General $356 24
2021 General $486 30
2020 General $421 18
2019 General $582 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Herman
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to David Herman were reported at $783. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year David Herman Infectious Disease median Middle half National median
2019 $582 $190 $60–$862 $163
2020 $421 $124 $32–$606 $114
2021 $486 $148 $38–$905 $132
2022 $356 $166 $50–$834 $149
2023 $700 $171 $57–$787 $160
2024 $857 $176 $52–$752 $164
2025 $783 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $1,073 42 payments
  2. ViiV Healthcare Company $676 37 payments
  3. Merck Sharp & Dohme Corporation $398 22 payments
  4. AbbVie, Inc. $352 11 payments
  5. Shionogi Inc $284 7 payments
  6. Melinta Therapeutics, Inc. $244 4 payments
  7. Insmed, Inc. $222 14 payments
  8. Janssen Biotech, Inc. $209 15 payments
  9. Paratek Pharmaceuticals, Inc. $125 3 payments
  10. Aimmune Therapeutics, Inc. $125 1 payment
  11. Other $477 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,109 169 payments
  2. Education $77 4 payments
Products named General payments · program years 2019–2025
  1. DOVATO $422 28 payments
  2. DIFICID $346 18 payments
  3. Fetroja $284 7 payments
  4. ZINPLAVA $223 9 payments
  5. Arikayce $205 13 payments
  6. SYMTUZA $181 12 payments
  7. Rezzayo $150 3 payments
  8. DALVANCE $149 3 payments
  9. TEFLARO $138 2 payments
  10. NUZYRA $125 3 payments
  11. Other $1,726 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

331

Median for Infectious Disease: 268

Drug cost

$681,576

Median for Infectious Disease: $217,595

Branded share of claims

82.5%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dovato Dolutegravir Sodium/Lamivudine Brand 194 $590,980
Tivicay Dolutegravir Sodium Brand 19 $46,987
Triumeq Abacavir/Dolutegravir/Lamivudi Brand 11 $41,135
Valacyclovir Valacyclovir Hcl Brand 19 $706
Rifampin Generic 16 $667
Doxycycline Hyclate Generic 15 $370
Linezolid Generic 12 $293
Azithromycin Generic 15 $197
Ceftriaxone Ceftriaxone Sodium Brand 12 $126
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $116

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$176,134

Of which drugs: $5,656

Medicare patients

794

Average age 78

Services billed

1,871

375 women, 419 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 58%
Diabetes 52%
Heart failure 51%
Chronic kidney disease 51%
Atrial fibrillation 47%
Depression 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
APRETUDE
  • ViiV Healthcare Company $122
$122 — —
Fetroja
  • Shionogi Inc $120
$120 — —
DOVATO
  • ViiV Healthcare Company $103
$103 194 —
Arikayce
  • Insmed, Inc. $100
$100 — —
CABENUVA
  • ViiV Healthcare Company $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record